Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey

INTRODUCTION: Talimogene laherparepvec is a first-in-class oncolytic immunotherapy for intratumoral injection with proven efficacy and tolerability in patients with unresectable early metastatic melanoma (stage IIIB–IVM1a) in the pivotal phase III OPTiM study. The objective was to characterize melan...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohr, Peter, Haferkamp, Sebastian, Pinter, Andreas, Weishaupt, Carsten, Huber, Margit A., Downey, Gerald, Öhrling, Katarina, Loquai, Carmen, Louie, Karly S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318239/
https://www.ncbi.nlm.nih.gov/pubmed/30536143
http://dx.doi.org/10.1007/s12325-018-0850-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318239/
https://www.ncbi.nlm.nih.gov/pubmed/30536143
http://dx.doi.org/10.1007/s12325-018-0850-6

Ejemplares similares